Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

NewGene introduces hereditary breast cancer test in France, Germany

UK based molecular diagnostic company NewGene, jointly owned by Newcastle Hospitals NHS Foundation Trust and Newcastle University, has introduced a new genetics test for hereditary breast cancer in France and Germany.

NewGene said the new hereditary breast cancer test identifies all mutations in the coding regions of two genes associated with inherited breast cancer – BRCA1 and BRCA2 – and not only reduces the amount of time that women have to wait for their results but will cost much less to provide.

The launch follows two years of test development work which has combined the sequencing and genotyping technologies, NewGene’s clinical expertise and developed data analysis software that enables high volume testing of gene sequences to be undertaken at a level not previously possible.

NewGene is also working in collaboration with UK NHS regional genetics services in Birmingham and London to offer conventional testing services for 50 hereditary diseases including colon cancer, various neuropathies, overgrowth syndromes such as Noonans and muscular dystrophies.